Skip to Main Content

The Washington Department of Health is reviewing a complaint that Sun Pharmaceuticals (SUNPHARMA) has been distributing samples of medicines in the state for more than two years without the necessary license, the second time one of the world’s largest generic drug makers has been probed for such an infraction amid scrutiny of several of its business practices.

A department spokeswoman explained that the complaint is currently being reviewed, but this is in the “very early stages of the process” and that the state Pharmacy Commission must still determine whether there is sufficient evidence to warrant a full-blown investigation. She did not say, though, how long this may take or whether a timeline exists to make a decision.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Since last few years, Sun is found in some or other controversies. Despite this, no brokerage house is giving any red signal to this stock. This creates their vested interest or some kind of hand in glove connivance with the management.

  • MANY COMPETITORS OF SUN PHARMA ARE POSSIBLY INVOLVED IN CLANDESTINE ACTIVITIES OF PULLING DOWN SUN PHARMA BY RUMOR SPREADING & MANIPULATING CONTINUATION OF SOME OR OTHER MINOR ISSUES DURING INSPECTION. FALSEHOOD CAN EXIST FOR SOMETIMES BUT ULTIMATELY TRUTH ONLY WILL PREVAIL AND SUN(PHARMA) WILL SHOW IT’S SUPREMACY.

Comments are closed.